• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Survey: 75% clinical trials collection processes are paperless

Survey: 75% clinical trials collection processes are paperless

June 20, 2016
CenterWatch Staff

SCORR Marketing, a global health science marketing and communications firm, in partnership with Applied Clinical Trials, has released the results of a comprehensive survey on the use of paperless processes in clinical trials.

The report describes current levels of paperless data collection, perspectives on the importance of paperless clinical trials and the processes that have already been adopted.

“From the survey, we discovered that nearly a quarter of users said that more than 75% of their data collection processes are paperless,” said Cliff Echols, director of market intelligence at SCORR Marketing. “Respondents said that the key benefit of going paperless is better data quality, and users said that their companies have primarily implemented processes to obtain trial data source records from electronic medical records (EMR) as well as processes to implement electronic signatures on clinical trial documents.”

Information regarding the benefits and challenges emerging from the adoption of eClinical processes was also gathered, as well as which stakeholders are most resistant to paperless trials and predictions on future company and industry adoption of paperless processes.

“Survey respondents said that the top concerns they are seeing from adopting paperless processes are related to data security,” said Echols.

“We found that the cost of technology and fear of change were the two greatest hindrances to the adoption of paperless processes,” said Lisa Henderson, editor in chief at Applied Clinical Trials, a part of the life sciences unit of UBM. “However, many respondents, particularly those working within a CRO, believe that there will still be a dramatic increase in their company’s use of paperless processes over the next three years.”

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing